Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment

Introduction: Chronic HC leads to the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). The treatment of chronic HC with DAAs reduces mortality from LC and HCC. The study aimed to investigate the serological markers specific to HCC (PIVKA-II and AFP) in patients with chronic H...

Full description

Bibliographic Details
Published in:	Journal of Infection in Developing Countries
Main Authors:	Sona Sargsyan, Hripsime Magdesieva, Tsoghik Navoyan, Aregnaz Mkhitaryan, Lusine Atoyan, Violeta Sargsyan, Hayk Harutyunyan, Vahe Azatyan, Armine Minasyan, Naira Gyulazyan
Format:	Article
Language:	English
Published:	The Journal of Infection in Developing Countries 2024-05-01
Subjects:	Chronic HCV infection hepatocellular carcinoma liver cirrhosis direct-acting antiviral agents
Online Access:	https://jidc.org/index.php/journal/article/view/18410

Similar Items

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
by: Luca Rinaldi, et al.
Published: (2019-08-01)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
by: Hafiza Arooba Riaz, et al.
Published: (2023-05-01)

Liver cirrhosis: dispensary observation, the effectiveness of antiviral therapy
by: Y.H. Yupatau, et al.
Published: (2022-08-01)

Effect of Direct-Acting Antivirals on Lipid and Glucose Metabolism in Chronic HCV Patients
by: Mohammed Mohammed, et al.
Published: (2019-07-01)

ASSESSMENT OF CARDIAC FUNCTIONS IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS BEFORE AND AFTER TREATMENT WITH DIRECTLY ACTING ANTIVIRALS
by: ESLAM S. MOHAMED, et al.
Published: (2021-08-01)

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01)

Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection
by: El-Araby Mohamed Ibrahim Shalaby, et al.
Published: (2023-06-01)

Topical problems of antiviral therapy for chronic hepatitis C
by: I G Bakulin
Published: (2015-11-01)

Hepatitis C: sociodemographic and clinical profile of patients treated with direct-acting antivirals in a pharmaceutical office
by: Karem Aline Pegoraro, et al.
Published: (2023-11-01)

Gender as a factor affecting NK cell activity in patients successfully treated for chronic hepatitis C with direct-acting antivirals
by: Agata Zientarska, et al.
Published: (2021-12-01)

Combined use of direct antiviral drugs - paritrapevir, ritonavir, ombitasvir and dasabuvir in the treatment of patients with HCV-deterministic compensated cirrhosis in real clinical practice
by: Yu. M. Ambalov, et al.
Published: (2018-06-01)

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination
by: Dorota Zarębska-Michaluk, et al.
Published: (2024-10-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients
by: Asmaa M. Elbrolosy, et al.
Published: (2021-03-01)

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
by: Christopher Dietz, et al.
Published: (2022-06-01)

Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
by: S N Batskikh, et al.
Published: (2018-11-01)

The impact of antiviral therapy on hepatocellular carcinoma epidemiology
by: Massimo Colombo, et al.
Published: (2018-01-01)

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-10-01)

Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study
by: Mehdi Kashani, et al.
Published: (2024-10-01)

CIRCULATING MIRNA-122, MIRNA-155, AND MIRNA- 200 AS PREDICTORS FOR HEPATOCELLULAR CARCINOMA OCCURRENCE IN EGYPTIAN PATIENTS WITH HEPATITIS C RELATED LIVER CIRRHOSIS TREATED WITH DIRECT ACTING ANTIVIRAL DRUGS
by: Hanan Nafeh, et al.
Published: (2024-06-01)

Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report
by: Michiko Shimada, et al.
Published: (2017-03-01)

The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection
by: D. V. Garbuzenko
Published: (2021-11-01)

Serum retinol-binding protein 4 as a predictor of fibrosis regression and response to direct-acting antiviral drugs in chronic hepatitis C virus patients
by: Hany Samir Rasmy, et al.
Published: (2023-03-01)

Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis
by: Liwei Zhuang, et al.
Published: (2021-07-01)

The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients
by: Meng-Yu Ko, et al.
Published: (2025-02-01)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
by: Nobuyuki Toshikuni
Published: (2017-05-01)

Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy
by: Chun-Hsien Chen, et al.
Published: (2023-01-01)

Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-05-01)

A study on the prevalence of HCV genotypes and the effect of direct-acting antiviral therapy on clinical and laboratory parameters in HCV-Infected patients at a tertiary care center in North India
by: S Muhammed Shahanas, et al.
Published: (2024-01-01)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
by: Devis Pascut, et al.
Published: (2020-06-01)

Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study
by: Filomena Morisco, et al.
Published: (2024-09-01)

Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States
by: Haesuk Park, et al.
Published: (2023-04-01)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
by: Hassan AM, et al.
Published: (2018-06-01)

Virologic Tools for HCV Drug Resistance Testing
by: Slim Fourati, et al.
Published: (2015-12-01)

Telemedicine and hybrid engagement models facilitate hepatitis C cascade of care during periods of healthcare disruption
by: Sabrina Fan, et al.
Published: (2026-01-01)

Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01)

Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug–Drug Interactions with Antiviral Treatments for Hepatitis C
by: Andreas Hintz, et al.
Published: (2021-05-01)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Weight Gain and Increased Body Mass Index in Patients with Hepatitis C after Eradication Using Direct-Acting Antiviral Therapy in Taiwan
by: Chun-Hsien Chen, et al.
Published: (2024-01-01)